Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

May 3, 2017Journal of diabetes and its complications

How losing weight is linked to changes in estimated kidney function: Analysis of two clinical trials

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Weight loss with liraglutide 3.0mg resulted in a mean weight loss of 8.0% in participants without type 2 diabetes over 56 weeks.

No significant changes in serum creatinine levels were observed after weight loss in either trial group.
Baseline serum creatinine levels were 76μmol/L for liraglutide participants and 74μmol/L after 56 weeks in the SCALE Obesity and Prediabetes trial.
In the SCALE Diabetes trial, baseline serum creatinine was 79μmol/L and remained unchanged at 79μmol/L after 56 weeks.
Weight loss percentages were 8.0% for liraglutide and 2.6% for placebo in SCALE Obesity and Prediabetes, while in SCALE Diabetes, they were 5.9% and 2.0%, respectively.
No association was found between changes in weight and changes in serum creatinine levels across both trials.

AI simplified

AIMS: Weight loss-induced serum creatinine reduction may increase creatinine-based estimated glomerular filtration rate (eGFR) producing incorrect estimates of kidney function. We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.

METHODS: Post hoc analysis of two 56-week, randomized, double-blind trials: SCALE Obesity and Prediabetes (n=3731, without type 2 diabetes [T2D], randomized [2:1] to liraglutide 3.0mg [n=2487] or placebo [n=1244]); SCALE Diabetes (n=846 with T2D, randomized [2:1:1] to liraglutide 3.0mg [n=423], 1.8mg [n=211, excluded from this analysis] or placebo [n=212]). NCT01272219/NCT01272232.

RESULTS: In SCALE Obesity and Prediabetes, mean (±SD) weight loss (baseline to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo); baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar across treatment groups). In SCALE Diabetes, weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo); baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo). No association between changes in weight and changes in serum creatinine was observed (P≥0.05, both trials, all tests).

CONCLUSIONS: Moderate gradual body weight reductions observed in the SCALE program were not associated with changes in serum creatinine.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief